SCHEMBL2324314

SCHEMBL2324314

OCCCNc1nnc(-c2ccccc2)c(-c2ccccc2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.56
KDM4E B2RXH2 4/20 0.56
HPGD P15428 4/20 0.56
KMT2A Q03164 1/20 0.56
ATM Q13315 1/20 0.56
SMN1; SMN2 Q16637 4/20 0.54
GAA P10253 3/20 0.54
LMNA P02545 2/20 0.54
ADORA1 P30542 2/20 0.53
GLA P06280 1/20 0.52
GPR84 Q9NQS5 1/20 0.52
HIF1A Q16665 1/20 0.52
KCNH3 Q9ULD8 2/20 0.51
POLB P06746 2/20 0.48
RAD52 P43351 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
MAPK1 P28482 1/20 0.46
CASP1 P29466 1/20 0.46
RAB9A P51151 1/20 0.46
CASP7 P55210 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31582428 0.90 ALDH1A1 (0.63) ALDH1A1KDM4EHPGDKMT2AATM
SCHEMBL2323024 0.90 ALDH1A1 (0.63) ALDH1A1KDM4EHPGDKMT2AATM
SCHEMBL2320673 0.85 SMN1; SMN2 (0.57) ALDH1A1KDM4EHPGDKMT2AATM
SCHEMBL2321152 0.84 GPR84 (0.55) ALDH1A1KDM4EHPGDKMT2AATM
SCHEMBL2326504 0.81 TP53 (0.52) ALDH1A1KDM4EHPGDSMN1; SMN2GAA
SCHEMBL2325810 0.80 GPR84 (0.48) ALDH1A1KDM4EHPGDKMT2AATM
SCHEMBL10815415 0.77 ALDH1A1 (0.55) ALDH1A1KDM4EHPGDKMT2AATM
SCHEMBL31582295 0.77 KCNH3 (0.54) ALDH1A1KDM4EHPGDSMN1; SMN2GAA
SCHEMBL31582439 0.76 GAA (0.51) ALDH1A1KDM4EHPGDSMN1; SMN2GAA
SCHEMBL31582446 0.76 GAA (0.51) ALDH1A1KDM4EHPGDSMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12054472-B2 1,2,4-triazine-4-amine derivatives NXERA PHARMA UK LIMITED (GB) 2024-08-06 US disclosed
US-20230021177-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES NXERA PHARMA UK LIMITED (GB) 2023-01-19 US disclosed
US-10988455-B2 1,2,4-triazine-4-amine derivatives HEPTARES THERAPEUTICS LIMITED (GB) 2021-04-27 US disclosed
US-20190047978-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES NXERA PHARMA UK LIMITED (GB) 2019-02-14 US disclosed
US-10112923-B2 1,2,4-triazine-4-amine derivatives HEPTARES THERAPEUTICS LIMITED (GB) 2018-10-30 US disclosed
US-20170291888-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES NXERA PHARMA UK LIMITED (GB) 2017-10-12 US disclosed
US-20160175314-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES HEPTARES THERAPEUTICS LIMITED (GB) 2016-06-23 US disclosed
EP-2531492-B1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES HEPTARES THERAPEUTICS LTD (GB) 2016-04-13 EP disclosed
US-9249130-B2 1,2,4-triazine-4-amine derivatives HEPTARES THERAPEUTICS LIMITED (GB) 2016-02-02 US disclosed
US-20150005276-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES NXERA PHARMA UK LIMITED (GB) 2015-01-01 US disclosed
US-8809525-B2 1,2,4-triazine-4-amine derivatives HEPTARES THERAPEUTICS LIMITED (GB) 2014-08-19 US disclosed
US-20130029963-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES HEPTARES THERAPEUTICS LIMITED (GB) 2013-01-31 US disclosed
EP-2531492-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES Heptares Therapeutics Limited (GB) 2012-12-12 EP disclosed
WO-2011095625-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES HEPTARES THERAPEUTICS LIMITED (GB) 2011-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150005276-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES ADORA2B, ADORA2A, ADORA1 ALDH1A1 784/4885KDM4E 3814/4885HPGD 436/4885
US-20190047978-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES ADORA2B, ADORA2A, ADORA1 ALDH1A1 784/4885KDM4E 3814/4885HPGD 436/4885
US-10988455-B2 1,2,4-triazine-4-amine derivatives ADORA2B, ADORA2A, ADORA1 ALDH1A1 784/4885KDM4E 3814/4885HPGD 436/4885
US-20160175314-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES ADORA2B, ADORA2A, ADORA1 ALDH1A1 794/4885KDM4E 3851/4885HPGD 439/4885
US-20230021177-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES ADORA2B, ADORA2A, ADORA1 ALDH1A1 788/4885KDM4E 4021/4885HPGD 389/4885
US-10112923-B2 1,2,4-triazine-4-amine derivatives ADORA2B, ADORA2A, ADORA1 ALDH1A1 763/4885KDM4E 3847/4885HPGD 486/4885
US-12054472-B2 1,2,4-triazine-4-amine derivatives ADORA2A, ADORA2B, ADORA1 ALDH1A1 251/4885KDM4E 3861/4885HPGD 1881/4885
US-20170291888-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES PTGER1, LTB4R2, LTB4R ALDH1A1 1211/4885KDM4E 3792/4885HPGD 365/4885
US-20130029963-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES ADORA2B, ADORA2A, ADORA1 ALDH1A1 784/4885KDM4E 3814/4885HPGD 436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.